{Reference Type}: Journal Article
{Title}: Identifying a Level of Neutralizing Antibody That Correlates With Protection From Clinical Mumps Disease During a 2017 Mumps Outbreak Among Military Service Members.
{Author}: Sowers SB;Clemmons NS;Mercader S;Nielsen L;Colley H;Jordan NN;Bettger CC;Masters NB;Markelz AE;Hickman CJ;
{Journal}: Open Forum Infect Dis
{Volume}: 11
{Issue}: 7
{Year}: 2024 Jul
{Factor}: 4.423
{DOI}: 10.1093/ofid/ofae329
{Abstract}: UNASSIGNED: In 2017, a mumps outbreak occurred in a US military barracks. Serum collected at service entry was used to compare pre-exposure with presumptive vaccine-induced antibody levels from persons who developed mumps (cases) and potentially exposed persons who did not develop mumps (non-cases). Sufficient information to determine levels of exposure during the outbreak was not available.
UNASSIGNED: Pre-outbreak serum samples from the Department of Defense Serum Repository were available from 254 potentially exposed service members. Twelve developed clinical symptoms and had post-outbreak serum collected. All sera were tested with a mumps-specific enzyme immunoassay for immunoglobulin M, immunoglobulin G (IgG), and IgG avidity. The neutralizing antibodies to vaccine strain (Jeryl Lynn [JL], genotype A) and wildtype virus (genotype G) was assessed by a plaque reduction neutralization test. A Fisher exact test and receiver operator characteristic curve were used to analyze the antibody response for non-cases and mumps cases.
UNASSIGNED: Eight mumps cases were laboratory confirmed. Pre-outbreak neutralizing antibody titers to JL and genotype G mumps virus and pre-outbreak IgG index values were proportionately lower for most cases as compared with exposed non-cases. When compared with potentially exposed non-cases, cases with clinical symptoms had greater odds of having a pre-outbreak JL titer <41 and a genotype G titer <16.
UNASSIGNED: We identified potential correlates of protection for mumps neutralizing antibody titers against JL and genotype G mumps viruses.